Compendium of Cancer Genome Aberrations

Volunteer Assignments and Opportunities: Difference between revisions

← Older editNewer edit →
VisualWikitext
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
Snehal.Patel (talk | contribs)
editor
270 edits
No edit summary
(105 intermediate revisions by 7 users not shown)
Line 1: Line 1:
ALK positive large B cell lymphomaALK positive large B cell lymphomaWelcome! 


*For assignments, please see the "Author" column below.  If no name is present, volunteer to create content!
*We will be creating content for all entities with genetic findings in the current WHO Classification of Tumours books.  '''<u>If there is an entity not yet listed below that you would like to author in any WHO book, we would be happy to create a page for you now</u>'''.
*To volunteer, please '''[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]''' with your page of interest.
__TOC__
==WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content==
{| class="wikitable"
{| class="wikitable"
|+WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Content
|-
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Disease'''!!'''Page Type'''!!'''Author'''
Line 23: Line 17:
|
|
|Fabiola Quintero-Rivera (FQR)
|Fabiola Quintero-Rivera (FQR)
|Date page was created
|
|
|
|-
|-
Line 33: Line 27:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 43: Line 37:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 67: Line 61:
|-
|-
|    Essential  Thrombocythaemia (ET)||Disease
|    Essential  Thrombocythaemia (ET)||Disease
|Rebecca Smith
|Rebecca Smith (trainee) + Fabiola Quintero-Rivera
|
|
|
|
|complete
|complete/pending faculty review
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|    Chronic Eosinophilic  Leukemia, Not Otherwise Specified||Disease
|Chelsea D. Kramish (trainee), Daynna J.Wolff
|(trainee), Daynna J.Wolff
|
|
|
|
|complete/pending faculty review
|pending faculty review
|
|
|FQR
|FQR
Line 88: Line 82:
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|    Myeloproliferative  Neoplasm (MPN), Unclassifiable||Disease
|Thomas Lee
|Thomas Lee
|
|8/17/2020
|
|9/7/2020
|complete
|complete
|
|
Line 96: Line 90:
|
|
|-
|-
|'''''Mastocytosis'''''||'''''Overview'''''||Shashi Shetty, Ph.D.
|'''''Mastocytosis'''''||'''''Overview'''''||'''Shashi Shetty, Ph.D.'''
|
|
|
|
Line 105: Line 99:
|-
|-
|    Cutaneous  Mastocytosis||Disease
|    Cutaneous  Mastocytosis||Disease
|Thuy Phung + Shuo-Shawn Liu (trainee)
|Thuy Phung/Shuo-Shawn Liu
|
|
|
|
|complete
|complete/pending adding content online as of 2/4/21
|
|
|FQR
|FQR
|
|
|8/1/21 FQR deleted "'''This page is under construction'''
|
|-
|-
|    Systemic Mastocytosis||Disease
|    Systemic Mastocytosis||Disease
Line 125: Line 119:
|-
|-
|    Mast Cell Sarcoma||Disease
|    Mast Cell Sarcoma||Disease
|Thuy Phung +Jordan Lowery (trainee)
|Thuy Phung +Jordan Lowery
|
|
|
|
Line 181: Line 175:
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Myeloid/Lymphoid Neoplasms with ETV6-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee)-Hindman + Daynna J. Wolff
|
|
|
|
Line 192: Line 186:
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Myeloid/Lymphoid Neoplasms with BCR-JAK2
|Disease
|Disease
|Lauren R. Crowson-Hindman (trainee) + Daynna J. Wolff
|Lauren R. Crowson (trainee) + Daynna J. Wolff
|
|
|
|
Line 231: Line 225:
|
|
|9/1/20
|9/1/20
|PENDING importing content and reference formatting
|PENDING
|
|
|FQR
|FQR
|
|
|FQR has emailed SR several times, last 4/20/22
|
|-
|-
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
|     Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts  and Thrombocytosis (MDS/MPN-RS-T)||Disease||Anamaria Munteanu (trainee)+Fabiola Quintero-Rivera
Line 243: Line 237:
|
|
|FQR
|FQR
|Date page was created
|
|
|
|-
|-
Line 255: Line 249:
|
|
|-
|-
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Jack Reid (trainee)+Fabiola Quintero-Rivera
|'''''Myelodysplastic Syndromes (MDS)'''''||'''''Overview'''''||Teresa Smolarek?
|
|
|4/21/22
|9/1/20
|pending
|pending
|
|
Line 293: Line 287:
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|    Myelodysplastic Syndrome (MDS) with  Multilineage Dysplasia||Disease||Xiaoli Du(trainee)+Teresa Smolarek
|
|
|
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 303: Line 297:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 330: Line 324:
|
|
|9/1/20
|9/1/20
|Complete
|PENDING
|
|
|FQR
|FQR
Line 364: Line 358:
|
|
|
|
|''<s>PENDING</s> Complete - awaiting clarification''
|PENDING
| ||JH / MS
| ||JH / MS
|04/26/2021 -MS (re-review)
|04/26/2021 -MS (re-review)
|Review completed, awaiting some clarification from JH - 07/04/2022
|
|-
|-
|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease||Fei Yang
|    Myeloid Neoplasms with Germline DDX41  Mutation||Disease||Fei Yang
Line 474: Line 468:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg
|    Acute Myeloid Leukemia (AML) with  BCR-ABL1||Disease||Kay Weng Choy + Greg Conboy (Monash Health)
Corboy (Monash Health)
|
|
|
|
Line 483: Line 476:
|
|
|-
|-
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu
|    Acute Myeloid Leukemia (AML) with  Mutated NPM1||Disease||Xinjie Xu+Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 491: Line 484:
|Add WHO reference
|Add WHO reference
|-
|-
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Corboy (Monash Health)
|    Acute Myeloid Leukemia (AML) with  Biallelic Mutations of CEBPA||Disease||Paul deFazio, MSc + Greg  Conboy (Monash Health)
|
|
|
|
Line 709: Line 702:
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
|Acute  Myeloid Leukemia (AML) with Mutated FLT3
|Disease
|Disease
|Kay Weng Choy + Greg Corboy (Monash Health)
|Kay Weng Choy + Greg Conboy (Monash Health)
|
|
|
|
Line 764: Line 757:
|
|
|-
|-
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain (trainee) + Yassmine Akkari
|    B-Lymphoblastic  Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1    ||Disease||Afia Hasnain + Yassmine Akkari
|
|
|
|
Line 836: Line 829:
|
|
|
|
|Complete
|PENDING
| ||YA
| ||YA
|
|
Line 929: Line 922:
| ||YA
| ||YA
|
|
|2021 template added
|
|-
|-
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
|NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang
Line 937: Line 930:
| ||YA
| ||YA
|
|
|2021 template added
|
|-
|-
| || ||
| || ||
Line 955: Line 948:
|
|
|-
|-
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||Jamie Nagy
|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease||
|10/25/21
|
|
|
|
|PENDING
|
|
|SP
|SP
Line 971: Line 964:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|B-cell Prolymphocytic Leukemia||Disease||Zejuan Li
|B-cell Prolymphocytic Leukemia||Disease||
|4/28/22
|
|
|
|
|PENDING
|
|
|SP
|SP
|
|
|2021 template added
|
|-
|-
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
|Splenic Marginal Zone Lymphoma||Disease||Snehal Patel
Line 1,027: Line 1,020:
|
|
|-
|-
|Lymphoplasmacytic Lymphoma||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
|Lymphoplasmacytic Lymphoma||Disease||
|
|
|
|
|
|PENDING
|
|
|SP
|SP
|
|
|2021 template added
|
|-
|-
|   Waldenstrom  Macroglobulinemia||Disease||Kapitolina Semenova (trainee)+Fabiola Quintero-Rivera
|   Waldenstrom  Macroglobulinemia||Disease||
|
|
|
|
|
|PENDING
|
|
|SP
|SP
|
|
|2021 template added
|
|-
|-
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
|IgM Monoclonal Gammopathy of Undetermined Significance||Disease||
Line 1,130: Line 1,123:
|
|
|-
|-
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||Chen Yang, MD, PhD
|'''''    Monoclonal  Immunoglobulin Deposition Diseases'''''||'''''Overview'''''||
|
|
|
|
|
|Complete
| ||SP
|09/10/2022||SP
|
|
|
|
|-
|-
|           Primary  Amyloidosis||Disease||Heather E. Williams, PhD
|           Primary  Amyloidosis||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|           Light Chain  and Heavy Chain Deposition Disease||Disease||Chen Yang, MD, PhD
|           Light Chain  and Heavy Chain Deposition Disease||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||Sohini Anand
|'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''||
|8/31/2021
|
|9/15/2021
|
|PENDING
|
| ||SP
| ||SP
|
|
|
|
|-
|-
|         POEMS Syndrome||Disease||Sohini Anand, MBBS, and Tharanga Niroshini Senaratne, PhD
|         POEMS Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|         TEMPI Syndrome||Disease||Sohini Anand, MBBS
|         TEMPI Syndrome||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee (trainee)/Fabiola Quintero-Rivera
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera
|3/9/21
|3/9/21
|
|
Line 1,185: Line 1,178:
|SP
|SP
|
|
|2021 template added
|
|-
|-
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
|Nodal Marginal Zone Lymphoma||Disease||Shivani Golem
Line 1,274: Line 1,267:
|
|
|-
|-
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||Mahsa Khanlari, MD
|    Leukemic Non-Nodal  Mantle Cell Lymphoma||Disease||
|
|
|
|
|
|?PENDING
|
|
|SP
|SP
Line 1,283: Line 1,276:
|
|
|-
|-
|    In Situ Mantle Cell  Neoplasia||Disease||Rina Kansal, MD
|    In Situ Mantle Cell  Neoplasia||Disease||
|6/12/22
|
|
|
|
|
|Complete
|7/26/2022
|SP
|SP
|
|
|2021 template added
|
|-
|-
| || ||
| || ||
Line 1,307: Line 1,300:
|Greg Corboy (GC)
|Greg Corboy (GC)
|
|
|Requested to update 14022022
|
|-
|-
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
|T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease||
Line 1,317: Line 1,310:
|
|
|-
|-
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||Laveniya Satgunaseelan
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease||
|26/10/2021
|
|26/1/2022
|
|Complete
|
|03/28/22||GC
| ||GC
|03/28/22
|
|2021 template added
|
|-
|-
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease||
Line 1,381: Line 1,374:
|
|
|-
|-
|Intravascular Large B-cell Lymphoma||Disease||Kate Berry, Greg Corboy
|Intravascular Large B-cell Lymphoma||Disease||
|25/01/2022
|
|25/4/2022
|
|Complete
|
|9/1/22||GC
| ||GC
|9/1/22
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|ALK-Positive Large B-cell Lymphoma||Disease||Nakasaki Manando
|ALK-Positive Large B-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note).  2021 template added.
|
|-
|-
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
|Plasmablastic Lymphoma||Disease||Mark Evans (trainee), Fabiola Quintero-Rivera
Line 1,402: Line 1,395:
|Complete
|Complete
| ||GC
| ||GC
|28/03/2022
|
|
|
|-
|-
Line 1,421: Line 1,414:
|
|
|-
|-
|   Multicentric Castleman  Disease||Disease||Sudha Arumugam
|   Multicentric Castleman  Disease||Disease||
|10/26/2021
|
|1/26/2022
|
|Complete
|
|24/01/2022||GC
|24/01/2022
|2021 template added
|-
|   HHV8-Positive Diffuse  Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||Xiao Zhou, MD, PhD, Siparadigm
|10/26/2021
|1/26/2022
|PENDING
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||Xiao Zhou, MD, PhD, Siparadigm
|   HHV8-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|10/26/2021
|
|1/26/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|Emailed 28/3/2022 for progress update
|
|-
|-
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|   HHV8-Positive  Germinotropic Lymphoproliferative Disorder||Disease||
|3/11/21
|06/28/2021
|Complete
|28/06/2021||GC
|28/06/2021
|
|-
|Burkitt-Like Lymphoma with 11q Aberration||Disease||Lauren Shealy (trainee), Daynna Wolff
|10/13/21
|01/13/2022
|Complete
|27/01/2022
|GC
|27/01/2021
|2021 template added
|-
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|
|
|
|
Line 1,470: Line 1,438:
|
|
|-
|-
|    High-Grade B-cell  Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||Kate Berry, Greg Corboy
|Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy
|30/05/21
|3/11/21
|30/08/21
|
|Complete
|PENDING
|24/02/2022||GC
| ||GC
|24/02/2022
|
|
|-
|    High-Grade B-cell  Lymphoma, Not Otherwise Specified (NOS)||Disease||Aiko Otsubo, Holli Drendel
|7/30/21
|10/30/21
|Complete
|15/11/2021
|GC
|16/11/2021
|
|
|-
|-
|B-cell Lymphoma, Unclassifiable, with Features Intermediate Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|Burkitt-Like Lymphoma with 11q Aberration||Disease||
|
|
|
|
Line 1,495: Line 1,454:
|
|
|-
|-
| || ||
|'''''High-Grade B-cell Lymphoma'''''||'''''Overview'''''||
|
|
|
|
|
|
| ||
| ||GC
|
|
|
|
|-
|-
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
|    High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements||Disease||
|
|
|
|
|
|
| ||Snehal Patel (SP)
| ||GC
|
|
|
|
|-
|-
|T-cell Prolymphocytic Leukemia||Disease||Michelle Don
|    High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||SP
|
|
|
|
|-
|-
|T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
|B-cell Lymphoma, Unclassifiable, with Features Intermediate  Between Diffuse Large B-cell Lymphoma and Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|PENDING
|
| ||SP
| ||GC
|
|
|
|
|-
|-
|Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
| || ||
|
|
|
|
|
|PENDING
| ||
| ||SP
|
|
|
|
|-
|-
|Aggressive NK-cell Leukemia||Disease||Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|'''''Mature T- and NK-cell Neoplasms'''''||'''''Overview'''''||
|
|
|
|
|
|?PENDING
| ||Snehal Patel (SP)
| ||SP
|
|
|
|
|-
|-
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of  Childhood'''''||'''''Overview'''''||
|T-cell Prolymphocytic Leukemia||Disease||Michelle Don
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
|T-cell Large Granular Lymphocytic Leukemia||Disease||Michelle Don
|
|
|
|
|Complete
|PENDING
|11/21/2021||SP
| ||SP
|
|
|
|
|-
|-
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
|Chronic Lymphoproliferative Disorder of NK Cells||Disease||Michelle Don
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Hydroa Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|Aggressive NK-cell Leukemia||Disease||
|
|
|
|
Line 1,575: Line 1,534:
|
|
|-
|-
|    Severe Mosquito Bite Allergy||Disease||
|'''''EBV-Positive T-cell and NK-cell Lymphoproliferative Diseases of Childhood'''''||'''''Overview'''''||
|
|
|
|
Line 1,583: Line 1,542:
|
|
|-
|-
|Adult T-cell Leukemia/Lymphoma||Disease||Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG
|  Systemic EBV-Positive  T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee)
|
|
|PENDING
| ||SP
|
|
|-
|   Chronic Active EBV  Infection of T- and NK-cell Type, Systemic Form||Disease||
|
|
|
| ||SP
|
|
|-
|    Hydroa  Vacciniforme-Like Lymphoproliferative Disorder||Disease||
|
|
|
| ||SP
|
|
|-
|    Severe Mosquito Bite  Allergy||Disease||
|
|
|
| ||SP
|
|
|-
|Adult T-cell Leukemia/Lymphoma||Disease||
|
|
|
|
|
|?PENDING
| ||SP
| ||SP
|
|
Line 1,669: Line 1,660:
|
|
|-
|-
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee), Tingting Barrett (trainee)
|Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee)
|
|
|
|
Line 1,677: Line 1,668:
|
|
|-
|-
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous CD30 Positive T-cell Lymphoproliferative  Disorders'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Lymphomatoid  Papulosis||Disease||Peining Li, PhD
|    Lymphomatoid  Papulosis||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||Theresa Spivey, MD, Shashirekha Shetty, PhD
|    Primary Cutaneous Anaplastic Large Cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||Peining Li, PhD
|'''''Primary Cutaneous Peripheral T-cell Lymphomas, Rare Subtypes'''''||'''''Overview'''''||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Gamma Delta T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||Peining Li, PhD
|     Primary Cutaneous Acral CD8+ T-cell Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
|
|
|-
|-
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||Peining Li, PhD
|     Primary Cutaneous CD4+ Small/Medium T-cell Lymphoproliferative Disorder||Disease||
|
|
|
|
|
|PENDING
| ||SP
| ||SP
|
|
Line 1,826: Line 1,817:
|
|
|-
|-
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||Thomas Harrington (resident) + Daynna Wolff
|Nodular Lymphocyte Predominant Hodgkin Lymphoma||Disease||
|06/22/2022
|
|09/22/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|2021 template added, Daynna organising
|
|-
|-
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
|'''''Classic Hodgkin Lymphoma'''''||'''''Overview'''''||
Line 1,842: Line 1,833:
|
|
|-
|-
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||Xiaolin (Lynn) Hu
|    Nodular Sclerosis  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|Completed
|03/21/22||GC
|03/21/22
|Edits sent 14022022
|-
|    Lymphocyte-Rich Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|
|
| ||GC
|
|
|PENDING
| ||GC
|
|
|2021 template added
|-
|-
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Lymphocyte-Rich  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|    Lymphocyte-Depleted Classic Hodgkin Lymphoma||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|    Mixed Cellularity Classic Hodgkin Lymphoma||Disease||
|
|
|
|
|
|PENDING
| ||GC
| ||GC
|
|
|2021 template added
|
|-
|-
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|    Lymphocyte-Depleted  Classic Hodgkin Lymphoma||Disease||
|
|
|
|
Line 1,882: Line 1,865:
|
|
|-
|-
|Lymphomas Associated with HIV Infection||Disease||Patricia V. Hernandez, M.D. (trainee)+Holli Drendel
|'''''Immunodeficiency-Associated Lymphoproliferative Disorders'''''||'''''Overview'''''||
|11/2/21
|
|02/02/22
|
|Completed
|
|03/21/22
| ||GC
|GC
|
|03/21/22
|
|2021 template added
|-
|Lymphomas Associated with HIV Infection||Disease||
|
|
|
| ||GC
|
|
|-
|-
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
|'''''Post-Transplant Lymphoproliferative Disorders'''''||'''''Overview'''''||
Line 1,907: Line 1,897:
|
|
|-
|-
|    Polymorphic  Post-Transplant Lymphoproliferative Disorders||Disease||Ania Shestakova (trainee) + Fabiola Quintero-Rivera
|    Polymorphic  Post-Transplant Lymphoproliferative Disorders||Disease||Anna Shestakova (trainee)''+,''
 
Fabiola Quintero-Rivera
|
|
|
|
|completed
|PENDING
|april 2022
|
|GC
|GC
|26/4/2022
|
|
|
|-
|-
Line 1,964: Line 1,956:
|
|
|-
|-
|Histiocytic Sarcoma||Disease||Marie-France Gagnon, MD, Mayo Clinic (LGG fellow trainee), Xinjie Xu, PhD FACMG, Mayo Clinic
|Histiocytic Sarcoma||Disease||
|
|
|
| ||GC
|
|
|
|
|Complete
|10/01/2021
|GC
|10/01/2021
|Xinjie Xu
|-
|-
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
|'''''Tumors Derived From Langerhans Cells'''''||'''''Overview'''''||
Line 1,981: Line 1,972:
|
|
|-
|-
|   Langerhans Cell  Histiocytosis||Disease||Malaika Perchard, Greg Corboy
|   Langerhans Cell  Histiocytosis||Disease||
|02/01/2022
|05/01/2022
|Complete
|04/28/2022||GC
|5/19/2022
|
|
|-
|   Langerhans Cell  Sarcoma||Disease||Malaika Perchard, Greg Corboy
|02/01/2022
|05/01/2022
|Complete
|04/28/2022||GC
|5/19/2022
|
|
|-
|
|Indeterminate Dendritic Cell Tumour||Disease||
| ||GC
|
|
|-
|   Langerhans Cell  Sarcoma||Disease||
|
|
|
| ||GC
|
|
|-
|Indeterminate Dendritic Cell Tumour||Disease||
|
|
|
|
Line 2,045: Line 2,036:
|
|
|-
|-
|Erdheim-Chester Disease||Disease||Prashant Deshpande
|Erdheim-Chester Disease||Disease||
|02/02/2022
|
|05/02/2022
|
|PENDING
|
| ||GC
| ||GC
|
|
|emailed 28/3/2022 to get update
|
|-
|-
| || ||
| || ||
Line 2,212: Line 2,203:
|
|
|
|
|}<br />
|}
 
==WHO Classification of Tumours of the Central Nervous System Content==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|Medulloblastoma, WNT-activated||Disease||Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City
|9/20/21
|
|PENDING
|
|Holli Drendel (interim)/Laveniya Satgunaseelan (LS)
|
|2021 template added
|-
|Paediatric-Type Diffuse High-Grade Gliomas
|Overview
|
|
|
|
|
|
|
|2021 template added
|-
|Diffuse Midline Glioma, H3 K27-Altered
|Disease
|Laveniya Satgunaseelan (Linda Cooley - previous version)
|
|
|
|
|Laveniya Satgunaseelan (LS)
|
|2021 template added
|-
|Diffuse Hemispheric Glioma, H3 G34-Mutant
|Disease
|Xiaolin (Lynn) Hu
|2/21/2022
|
|PENDING
|
|LS
|
|2021 template added
|-
|Diffuse Paediatric-Type High-Grade Glioma, H3-Wildtype and IDH-Wildtype
|Disease
|
|
|
|
|
|
|
|2021 template added
|-
|Infant-Type Hemispheric Glioma
|Disease
|
|
|
|
|
|
|
|2021 template added
|-
|Astrocytoma, IDH-Mutant
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|PENDING
|
|LS
|
|2021 template added
|-
|Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
|Disease
|Riley Lochner (trainee), Shashi Shetty (mentor)
|3/3/2022
|
|PENDING
|
|LS
|
|2021 template added
|-
|}<br />
 
==WHO Classification of Soft Tissue and Bone Tumours Content==
{| class="wikitable"
|-
!'''Disease'''!!'''Page Type'''!!'''Author'''
!'''Date Assigned to Author'''
!'''Target Completion Date'''
!'''Author Content (Pending or Complete)'''
!'''Date Completed by Author'''!!'''Associate Editor'''
!'''Date of Last Editor Review'''
!'''Notes'''
|-
|NTRK-Rearranged Spindle Cell Neoplasm||Disease||James Solomon, MD, PhD
|2/20/2022
|
|PENDING
|
|Alanna Church
|
|
|-
|}<br />
 
==Gene-Specific Pages (IN PROCESS OF AUTOMATING - HOLD ON VOLUNTEERING)==
{| class="wikitable sortable"
{| class="wikitable sortable"
|+Gene-Specific Pages
!'''Gene'''
!'''Gene'''
!'''Author'''
!'''Author'''
Retrieved from "https://content.ccga.io/index.php/Volunteer_Assignments_and_Opportunities"